$6.150
+0.315 (+5.13%)終値時点
TKNO のニュース
TKNO のイベント
Treasury Yields Retreat as Netflix Falls Over 5%
Treasury yields retreated across the curve on Tuesday as weak U.S. housing data dented the perception of resilient economic growth. Rate-sensitive and defensive areas of the market outperformed, with Healthcare and REITS seen as the best-performing sectors in the benchmark S&P 500. Communication Services - the worst sector in the S&P - struggled, as Meta Platformsextended its three-day decline as Muse-enfused sugar-high continued to wear off, with the stock now down 10% from last week's high.The earnings season shifted into a higher gear, with more high-profile names outside of the financial sector reporting results. Netflixwas down over 5% despite an earnings beat, as the company reduced its FY26 outlook for overall revenue and ad sales. SpaceXsoared however after broadly beating estimates and also indicating that the company has formed a strategic committee to consider a merger with Tesla.In the opening hour of the evening session S&P e-minis are up 0.2% and Nasdaq 100 futures are up 0.7%. In commodities, WTI crude oil is back above $98 a barrel after dipping to $95 following an unconfirmed report from Qatari newspaper Al-Araby Al-Jadeed that Qatar and Pakistan presented a mediation proposal that addresses the demands of the U.S. and Iran.Check out this evening's top movers from around Wall Street, compiled by The Fly.HIGHER AFTER EARNINGS -Space Exploration Technologiesup 7.2%Capital One Financialup 5.7%ALSO HIGHER -Super Micro Computerup 15.9% after Q1 pre-announcementDOWN AFTER EARNINGS -Intuitive Surgicaldown 6.9%Netflixdown 5.9%Pegasystemsdown 4.9%Stridedown 2.2%United Airlinesdown 1.0%ALSO LOWER -Alpha Teknovadown 22.2% after equity offering
Teknova Estimates Total Revenue Up 19% to 21%
The company said, "Teknova's total revenue is estimated to be up 19% to 21% compared to the same period in the prior year. Teknova's gross margin is estimated to have expanded by 500-700 basis points compared to the same period in the prior year, driven primarily by top-line growth. Teknova's estimated Adjusted EBITDA would represent an at least 25% improvement compared to the same period in the prior year, driven by continued cost discipline."
Alpha Teknova Commences Underwritten Public Offering of Common Stock
Alpha Teknova announced that it has commenced an underwritten public offering of its common stock. All of the shares of common stock to be sold in the proposed offering are to be sold by Teknova. Teknova currently intends to use the net proceeds from the proposed offering for general corporate purposes, including potentially the repayment of outstanding debt obligations. Teknova may use a portion of the net proceeds to acquire or invest in other businesses, products, and technologies that are complementary to its own, although Teknova has no current commitments or arrangements to do so. TD Cowen and William Blair are acting as joint book-running managers for the proposed offering.
Alpha Teknova and Pluristyx Complete Drug Master File for PluriFreeze System
Alpha Teknova and Pluristyx announced that Pluristyx is completing a Type II Drug Master File for the PluriFreeze cryopreservation system for submission to the U.S. FDA. The DMF will support drug makers seeking to incorporate PluriFreeze into their clinical development and manufacturing programs. Teknova is a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, and is the exclusive manufacturer and distributor of PluriFreeze in the United States and Canada. Pluristyx is a leading provider of advanced induced pluripotent stem cell technologies and proprietary, genetically engineered solutions for drug discovery and the development of advanced therapies. Developers who utilize PluriFreeze in preclinical stages can now request a letter of authorization from Pluristyx and cross-reference the PluriFreeze DMF in their Investigational New Drug applications and Biologics License Applications. The comprehensive regulatory submission details chemistry, manufacturing, and controls for the PluriFreeze system, helping to streamline regulatory submissions and accelerate the development of next-generation therapies.
Teknova Q1 Revenue $11.08M Beats Consensus
Reports Q1 revenue $11.08M, consensus $10.22M. "We had a great start to 2026," said Stephen Gunstream, President and Chief Executive Officer at Teknova. "The substantial investments we've made since 2021, combined with an improved market backdrop, position Teknova for sustainable above-market growth over the next couple years, particularly as our Clinical Solutions customers advance their therapies and diagnostics towards commercialization."
本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。





